This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Massa, G. Articles by De Schepper, J. Search for Related Content PubMed PubMed Citation Articles by Massa, G. Articles by De Schepper, J.

Late or Delayed Induced or Spontaneous Puberty in Girls with Turner Syndrome Treated with Growth Hormone Does Not Affect Final Height

Belgian Study Group for Pediatric Endocrinology (G.M., S.V., M.T.) and Departments of Pediatrics of the Universities of Antwerp (M.D.C.), Bruxelles (G.M., C.H.), Brussels (J.D.S.), Ghent (M.C.), Leuven (I.F.), Louvain (M.M.), and Liège (J.P.B.), Belgium

Address all correspondence and requests for reprints to: Guy Massa, M.D., Department of Pediatrics, University of Bruxelles, Avenue Jean Joseph Crocq 15, 1020 Bruxelles, Belgium. E-mail: guy.massa{at}planetinternet.be.

Although it has been well established that GH treatment increases final height (FH) in girls with Turner syndrome (TS), the optimal ages to start GH therapy and introduce estrogens for pubertal induction have not been defined. We evaluated retrospectively the influence of the age at onset of GH treatment and age at onset of puberty on FH of 186 adult TS women treated during childhood with GH. Puberty started spontaneously in 38 patients, and it was induced in 148 girls with ethinyl estradiol (mean ± SD starting dose, 66 ± 32 ng/kg·d). Patients with spontaneous or induced puberty were divided into quartiles on the basis of age at initiation of GH treatment (3–10, 10–12, 12–14, and 14–19 yr). FH was 151.7 ± 6.0 cm; there were no FH differences between patients with induced or spontaneous puberty, nor were there differences between the age quartiles. Puberty started earlier in the girls with spontaneous puberty than in those with induced puberty (12.4 ± 1.3 yr vs. 14.5 ± 1.9 yr; P < 0.0001). The age at onset of puberty was not related to FH. Pubertal growth was 15.4 ± 4.6 cm in the girls with spontaneous puberty and 8.6 ± 4.3 cm in the girls with induced puberty (P < 0.0001). We conclude that GH treatment results in a significant increase in FH in most TS girls. Under the conditions of GH treatment and induction of puberty that we have used, the age at start of GH treatment was not related to FH; in addition, late or delayed induced or spontaneous puberty did not affect FH.

This work was supported by grants from the Foundation of the Belgian Study Group for Pediatric Endocrinology.

Abbreviations: CMPH, Corrected midparental height; EE2, ethinyl estradiol; FH, final height; H-SDS, height SDS; SDS, SD score; TS, Turner syndrome.

This article has been cited by other articles:

				M. L. Davenport, B. J. Crowe, S. H. Travers, K. Rubin, J. L. Ross, P. Y. Fechner, D. F. Gunther, C. Liu, M. E. Geffner, K. Thrailkill, et al. Growth Hormone Treatment of Early Growth Failure in Toddlers with Turner Syndrome: A Randomized, Controlled, Multicenter Trial J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3406 - 3416. [Abstract] [Full Text] [PDF]

				M D C Donaldson, E J Gault, K W Tan, and D B Dunger Optimising management in Turner syndrome: from infancy to adult transfer Arch. Dis. Child., June 1, 2006; 91(6): 513 - 520. [Abstract] [Full Text] [PDF]

				L. Soriano-Guillen, J. Coste, E. Ecosse, J. Leger, M. Tauber, S. Cabrol, M. Nicolino, R. Brauner, the StaTur Study Group, J.-L. Chaussain, et al. Adult Height and Pubertal Growth in Turner Syndrome after Treatment with Recombinant Growth Hormone J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5197 - 5204. [Abstract] [Full Text] [PDF]

				J.-C. Carel Growth Hormone in Turner Syndrome: Twenty Years after, What Can We Tell our Patients? J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3793 - 3794. [Full Text] [PDF]

				The Canadian Growth Hormone Advisory Committee Impact of Growth Hormone Supplementation on Adult Height in Turner Syndrome: Results of the Canadian Randomized Controlled Trial J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3360 - 3366. [Abstract] [Full Text] [PDF]

				G Massa, F Verlinde, J De Schepper, M Thomas, J P Bourguignon, M Craen, F de Zegher, I Francois, M Du Caju, M Maes, et al. Trends in age at diagnosis of Turner syndrome Arch. Dis. Child., March 1, 2005; 90(3): 267 - 268. [Abstract] [Full Text] [PDF]

				G. Binder, A. Renz, A. Martinez, A. Keselman, V. Hesse, S. W. Riedl, G. Hausler, S. Fricke-Otto, H. Frisch, J. J. Heinrich, et al. SHOX Haploinsufficiency and Leri-Weill Dyschondrosteosis: Prevalence and Growth Failure in Relation to Mutation, Sex, and Degree of Wrist Deformity J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4403 - 4408. [Abstract] [Full Text] [PDF]